| ²é¿´: 1218 | »Ø¸´: 3 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
xiaotongxyzľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
ÇóÖú·ÒëÖÐÎÄÕªÒªÒ»·Ý£¬ÖØÉͽð±Ò£¬·ÒëµÄºÃ¿É×·¼Ó
|
||
|
ÔÎÄ£º ¹ú²úÀûÅàͪÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰÁÆÐ§·ÖÎö ÕªÒª£ºÄ¿µÄ£ºÌ½ÌÖ¹ú²úÀûÅàͪ£¨Ë¼ÀûÊæ£©ÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰÁÆÐ§ºÍ°²È«ÐÔ¡£·½·¨£ºËæ»ú³éÈ¡ÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ30Àý£¬ÓÃ˼ÀûÊæÖÎÁÆ£¬²¢·Ö±ðÓÚÖÎÁÆÇ°¼°ÖÎÁƺóµÚ1¡¢2¡¢4¡¢8ÖÜÄ©²ÅÈ¥¼òÃ÷¾«Éñ²¡Á¿±í£¨BPRS)¡¢ÑôÐÔÖ¢×´ÒõÐÔÖ¢×´Á¿±í£¨PANSS£©¼°¸±×÷ÓÃÁ¿±í£¨TCSS£©ÆÀ¶¨ÁÙ´²ÁÆÐ§¼°²»Á¼·´Ó¦¡£½á¹û£ºBPRS×Ü·Ö¡¢PANSS×ֺܷ͸÷Ö¢×´ÆÀ·Ö¾ù½ÏÖÎÁÆÇ°ÏÔÖø½µµÍ£¬ÇÒÓÐÏÔÖø²îÒ죨P<0.01~0.05£©£¬ÓÐЧÂÊ£º90%£¬ÏÔЧÂÊ£º63%£¬³£¼û²»Á¼·´Ó¦ÊÇÌåÖØÔö¼Ó¡¢¾²×ø²»ÄÜ¡£½áÂÛ£ºË¼ÀûÊæ¶ÔÄÔѪ¹ÜËùÖª¾«ÉñÕϰ°²È«ÓÐЧ£¬²»Á¼·´Ó¦ÉÙ£¬¾¼ÃÊÊÓã¬ÖµµÃÁÙ´²ÍƹãʹÓᣠ|
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
286·ÖÈ˹¤ÖÇÄÜרҵÇëÇóµ÷¼ÁÔ¸Òâ¿ç¿¼£¡
ÒѾÓÐ3È˻ظ´
329Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÉêÇë»Ø¸åÑÓÆÚÒ»¸öÔ£¬±à¼Í¬ÒâÁË¡£µ«ÏµÍ³ÉϵÄʱ¼äû±ä£¬¸ø±à¼ÓÖдÓʼþÁË£¬Ã»»Ø¸´
ÒѾÓÐ4È˻ظ´
²ÄÁÏѧ˶318Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Öйúº£Ñó´óѧ£¬ÉúÎïѧ£¬301·Ö£¬Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
081700»¯¹¤Ñ§Ë¶µ÷¼Á
ÒѾÓÐ3È˻ظ´

·Ç±ÈѰ³£
ľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 13
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 5027.7
- É¢½ð: 888
- Ìû×Ó: 163
- ÔÚÏß: 375.3Сʱ
- ³æºÅ: 894506
- ×¢²á: 2009-11-05
- ÐÔ±ð: GG
- רҵ: ÎÛȾÉú̬»¯Ñ§
xiaotongxyz(½ð±Ò+20, ·ÒëEPI+1):·ÒëµÄ²»¹»×¨Òµ£¬ÓÐЩ·Òë²»¹»×¼È·×¨Òµ 2010-04-30 01:18
|
Analysis of therapeutic effect of domestic Risperidone on non-psychotic disorders resulting from cerebrovascular diseases Abstract: Purpose: to probe into therapeutic effect and security of domestic Risperidone on non-psychotic disorders resulting from cerebrovascular diseases. Approach: to randomly draw 30 cases with non-psychotic disorders resulting from cerebrovascular diseases, treat them with Risperidone and then assess clinical curative effects and undesirable reactions with BPRS, PANSS and TCSS at the end of the first, second, fourth and eighth week before and after treatment. Result: aggregate score of BPRS and PANSS and each symptom score are considerablely much lower than that before treatment with significant variation (P<0.01~0.05). The effective rate is 90% and developing rate is 63%. Common undesirable reactions are gain in weight and loss of sitting still. Conclusion: Risperidone is secure and effective with a few undesirable reactions and deserves promotion and application because of its economically affordable and applicable trait on the treatment of non-psychotic disorders resulting from cerebrovascular diseases. |

2Â¥2010-04-29 21:53:09
pharmjackie
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 21
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 2210
- Ìû×Ó: 312
- ÔÚÏß: 180.4Сʱ
- ³æºÅ: 302356
- ×¢²á: 2006-12-02
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
xiaotongxyz(½ð±Ò+30):ǰ°ë²¿·Ö·ÒëºÜºÃ£¬ºó°ë²¿·Ö²»¹»ÀíÏ룬רҵÐÔÔÙǿЩ¾ÍºÃÁË 2010-04-30 01:22
|
efficacy of Risperidone on brain vascular diseases caused psychonosema Abstract Object: to evaluate the efficacy and safety of Risperidone on brain vascular diseases caused psychonosema. Method: A total of 30 patients with psychonosema was randomly selected to treat with Risperidone, and clinical efficacy and adverse effect was recorded using BPRS, PANSS, and TCSS before treatment and at the end of 1, 2, 4, 8 weeks after treatment. Results: BPRS scores, PANSS scores and symptom scores decreased significantly compared to that of pre-treatment (P<0.01~0.05). Effective percentage is 90% while the obvious effective rate is 63%. Common adverse effects include: Weight gain, akathisia. Conclusion: Risperidone¡¯s effectiveness, safety and minor adverse effect makes itself worthy of clinical use. |
3Â¥2010-04-29 22:10:21
xiaotongxyz
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2121.1
- É¢½ð: 10
- ºì»¨: 1
- Ìû×Ó: 380
- ÔÚÏß: 11.3Сʱ
- ³æºÅ: 325960
- ×¢²á: 2007-03-17
- ÐÔ±ð: GG
- רҵ: µ°°×ÖÊ×éѧ

4Â¥2010-05-07 11:58:31













»Ø¸´´ËÂ¥
10